Data Sheet

Product Name:	CLK-IN-T3
Cat. No.:	CS-0087015
CAS No.:	2109805-56-1
Molecular Formula:	$C_{28}H_{30}N_6O_2$
Molecular Weight:	482.58
Target:	CDK; DYRK
Pathway:	Cell Cycle/DNA Damage; Protein Tyrosine Kinase/RTK
Solubility:	DMSO : 4.83 mg/mL (10.01 mM; Need ultrasonic and warming)



BIOLOGICAL ACTIVITY:

CLK-IN-T3 is a high potent, selective, and stable **CDC-like kinase (CLK)** inhibitor with **IC_{50}**s of 0.67 nM, 15 nM, and 110 nM for CLK1, CLK2, and CLK3 protein kinases, respectively. CLK-IN-T3 has anti-cancer activity[1]. **In Vitro:** CLK-IN-T3 inhibits DYRK1A (IC_{50}=260 nM) and DYRK1B (IC_{50}=230 nM)[1].

CLK-IN-T3 (0.1-10.0 μM; 24 hours) results in mild cell cycle arrest at the G2/M boundary with long-duration (24 h)[1].

CLK-IN-T3 (0.5-1.0 μM; 6 hours) decreases phosphorylation of CLK-targeted SR proteins and CLK proteins increase slightly[1].

References:

[1]. Funnell T, et al. CLK-dependent exon recognition and conjoined gene formation revealed with a novel smallmolecule inhibitor. Nat Commun. 2017 Feb 23;8(1):7.

CAIndexNames:

Benzamide, 4-[1,1-dimethyl-2-(4-methyl-1-piperazinyl)-2-oxoethyl]-N-[6-(4-pyridinyl)imidazo[1,2-a]pyridin-2-yl]-

SMILES:

CC(C1=CC=C(C(NC2=CN3C=C(C4=CC=NC=C4)C=CC3=N2)=O)C=C1)(C)C(N5CCN(C)CC5)=O

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 732-484-9848 Fax: 888-484-5008 E-mail: sales@ChemScene.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA